Glactone Pharma Development AB
ABActiveAdvertising protectionOrg 5569121121Kungsportsavenyen 22, 411 36 GöteborgResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2012 · 13 years old0 employees
Loading company…
Overview
Glactone Pharma Development AB is a Swedish AB based in Göteborg, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2012, the company has 0 employees and reported revenue of SEK 120.0k in its latest annual filing.
Revenue 2025
120K SEK
+50% vs 2024
EBITDA margin
63.9 %
+177% vs 2024
Net profit 2025
45.6K SEK
+1481% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
56.3 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
2.1×
WeakAmong the 40% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
10.0 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
SEK thousandsKey figures
Annual report 2025| Revenue | 120K SEK | +50% |
| EBITDA | 76.6K SEK | +177% |
| Net profit | 45.6K SEK | +1481% |
| Total assets | 454.9K SEK | +2% |
| Equity | 256K SEK | +22% |
| Employees | 0 | — |
Company information
Legal name
Glactone Pharma Development AB
Org number
5569121121
Legal form
Aktiebolag
Founded
29 November 2012 · 13 years
Share capital
SEK 50,000
Employees
0 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva forskning, utveckling, utbildning, marknadsföring och försäljning inom det medicinska området samt idka därmed förnelig verksamhet.
(no translation available)
Contact
Address
Kungsportsavenyen 22, 411 36 Göteborg
Phone
+46706649477
Email
gj@forsalven.se
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Glactone Pharma Development AB reported revenue of SEK 120.0k, an increase of 50% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of SEK 45.6k, and the EBITDA margin stood at 63.9%.
At the end of 2025, equity financed 56.3% of the balance sheet, and current assets covered short-term debt 2.1 times.
Financials
Revenue
SEK thousandsEBITDA
SEK thousandsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 120 | 80 | 80 | 0 | 0 |
| Staff expenses | -0 | -0 | — | — | — |
| EBITDA | 77 | 28 | 39 | -18 | -238 |
| Depreciation & amort. | -31 | -31 | -28 | -19 | -17 |
| EBIT | 46 | -3 | 11 | -37 | -255 |
| Net financials | -0 | -0 | — | — | — |
| Profit before tax | 46 | -3 | 11 | -37 | -255 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 46 | -3 | 11 | -37 | -255 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 455 | 446 | 490 | 533 | 497 |
| Equity | 256 | 210 | 214 | 203 | 239 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 34 | 22 | 277 | 330 | 257 |
| Total debt | 34 | 22 | 277 | 330 | 257 |
Financial ratios
5-year trendEBITDA margin
63.9 %
20212025
Equity ratio
56.3 %
AverageAround the average of companies in the same industry
20212025
Return on equity
17.8 %
AverageAround the average of companies in the same industry
20212025
Net profit margin
38.0 %
StrongAmong the 30% highest rated companies in the industry
20212025
Asset turnover
0.26×
AverageAround the average of companies in the same industry
20212025
Debt / equity
0.78×
StrongAmong the 30% highest rated companies in the industry
20212025
Sector performance
27 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 30% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginStrong
Among the 30% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginStrong
Among the 30% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Average
Around the average of companies in the same industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Average
Around the average of companies in the same industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 40% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 20% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 40% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 20% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery weak
Among the 10% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 20% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 20% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 30% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityWeak
Among the 40% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtStrong
Among the 30% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery strong
Among the 20% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageStrong
Among the 30% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 40% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalWeak
Among the 40% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 30% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AH Chief Auditor | Chief Auditor | 2020 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JB Chairman | Chairman | 2020 |
AS Board of Directors | Board of Directors | 2020 |
DM Board of Directors | Board of Directors | 2022 |
Former (1)
KR Board of Directors | Board of Directors | 2020 – 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Glactone Pharma AB
Glactone Pharma Development AB Board network connections
Board members of Glactone Pharma Development AB also hold positions in 309 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Henrik Alexander Brodström | Chief Auditor | 285 companiesMany roles |
| Daniel Martin Lifveredson | Board of Directors | 14 companiesMany roles |
| Anders Sigvard Bjartell | Board of Directors | 7 companiesMany roles |
| Jan Birger Fredrik Törnell | Chairman | 3 companies |
Frequently asked questions
What is the Org number of Glactone Pharma Development AB?
Glactone Pharma Development AB is registered with Bolagsverket / SCB under Org 5569121121.
What is the revenue of Glactone Pharma Development AB?
Glactone Pharma Development AB reported revenue of SEK 120.0k in 2025.
Who is the chairman of Glactone Pharma Development AB?
Jan Birger Fredrik Törnell chairs the board of Glactone Pharma Development AB, in role since 2020.
Where is Glactone Pharma Development AB headquartered?
Glactone Pharma Development AB's registered address is Kungsportsavenyen 22.